Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients

M.D. Anderson Cancer Center · NCT03048266

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Any age listed · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
629
US sites recruiting
1
Study start
November 5, 2015
Record last updated
May 23, 2019

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Objectives

The aim of the present study is to assess the significance of metabolomics and genetics in diagnosing and survival evaluation for pNET in the periodic follow-up of MEN1 patients.

Aim 1: To evaluate the relationship of serum global metabolic profiles with subsequent development of aggressive PNET and evaluate patients survival in a nested case-control study of MEN1 patients who have developed aggressive PNETs (cases) and MEN1 patients who have developed non-aggressive PNETs (controls).

Aim 2: Validate the top serum metabolites identified from Aim 1 in MEN1 patients who have developed aggressive PNETs and MEN1 patients who have developed non-aggressive PNETs, using a targeted metabolomics approach.

Aim 3: Prospectively identify the potential miRNA biomarkers of serum with miRNA sequencing in MEN1 patients who have developed aggressive PNETs (cases) and MEN1 patients who have developed non-aggressive PNETs (controls).

Aim 4: Validate the potential miRNA biomarkers identified from Aim 1 in MEN1 patients who have developed aggressive PNETs and in MEN1 patients who have developed non-aggressive PNETs, using a targeted qRT-PCR approach (in serums), as well as to see the relationship of potential miRNA biomarkers with patients survival.

Conditions: Multiple Endocrine Neoplasia

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • The study will include all patients with a confirmed MEN1 diagnosis (clinical, genetic or familial criteria).
  • No prior history of PNET.

Exclusion Criteria

N/A

Recruiting US locations

  • University of Texas MD Anderson Cancer Center

    Houston, TX 77030

Study contacts (from the official record)

  • Nancy D. Perrier, MD · 713-792-6940 · NPerrier@mdanderson.org
All healthy volunteers studies in Texas →
Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine… (NCT03048266) | Bored Studies